Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

OGX-427 shows signs of efficacy in phase II trial

Feb. 6, 2012

Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer

Feb. 6, 2012

Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial

Feb. 6, 2012

VT-464 reduces tumor growth in prostate cancer model

Feb. 3, 2012

ARN-509 is well tolerated in phase I/II study

Feb. 3, 2012

Studies detail beta-amyloid detection with florbetapir F 18 PET

Jan. 27, 2012

Liposomal irinotecan shows benefit in metastatic colorectal cancer

Jan. 27, 2012

Panobinostat trial in colorectal cancer yields mixed results

Jan. 26, 2012

Kampo medicine reduces oxaliplatin-induced peripheral neuropathy in patients with cancer

Jan. 26, 2012

Cancer vaccine shows activity in phase I/II trial

Jan. 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...